Bioequivalence Study in Healthy Volunteers
This study has been completed.
Information provided by:
First received: October 11, 2006
Last updated: July 22, 2011
Last verified: July 2011
Primary: To determine the bioequivalence between the new formulation and the current formulation of the investigational drug, MOA-728.
|Study Design:||Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||An Open-label, Single-dose, Randomized, 2-period Crossover, Bioequivalence Study Between the Current Formulation and the New Formulation of MOA-728 Administered Subcutaneously in Healthy Subjects|
Further study details as provided by Salix Pharmaceuticals:
Contacts and Locations